Wound-Healing Product Jurisdiction To Be Challenged At June FDA Hearing
This article was originally published in The Gray Sheet
Executive Summary
FDA is considering whether to reassign primary jurisdiction of certain tissue-based products, such as interactive wound dressings, to the Center for Biologics Evaluation & Research
You may also be interested in...
Potential Jurisdictional Change Draws Protest From Wound Product Firms
Wound healing products for which a primary mode of action cannot be elucidated should remain under the jurisdiction of FDA's device center, according to Apligraf manufacturer Organogenesis
Potential Jurisdictional Change Draws Protest From Wound Product Firms
Wound healing products for which a primary mode of action cannot be elucidated should remain under the jurisdiction of FDA's device center, according to Apligraf manufacturer Organogenesis
CBER Tissue Products Office To Be Established By Oct. 1
CBER's Office of Cells, Tissues & Gene Therapy will address the "evolution" of scientific and regulatory issues, FDA Center for Biologics Evaluation & Research Director Kathryn Zoon said May 29